Profile data is unavailable for this security.
About the company
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
- Revenue in USD (TTM)0.00
- Net income in USD-179.53m
- Incorporated2013
- Employees112.00
- LocationAllovir Inc1100 Winter StreetWALTHAM 02451United StatesUSA
- Phone+1 (617) 433-2605
- Fax+1 (302) 655-5049
- Websitehttps://www.allovir.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sellas Life Sciences Group Inc | 0.00 | -35.81m | 81.43m | 16.00 | -- | 8.19 | -- | -- | -1.12 | -1.12 | 0.00 | 0.1721 | 0.00 | -- | -- | 0.00 | -133.77 | -111.48 | -303.59 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
Assembly Biosciences Inc | 12.95m | -51.36m | 83.53m | 65.00 | -- | 2.55 | -- | 6.45 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Gritstone bio Inc | 15.65m | -144.89m | 84.00m | 231.00 | -- | 5.44 | -- | 5.37 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
Ikena Oncology Inc | 3.85m | -70.09m | 85.42m | 34.00 | -- | 0.5499 | -- | 22.20 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
Chimerix Inc | 41.00k | -82.59m | 86.65m | 72.00 | -- | 0.4977 | -- | 2,113.52 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
Allovir Inc | 0.00 | -179.53m | 86.82m | 112.00 | -- | 0.7201 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 88.57m | 15.00 | 8.76 | 0.5301 | 8.48 | 131.41 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
Precision BioSciences Inc | 57.53m | -19.99m | 89.34m | 109.00 | -- | 2.40 | -- | 1.55 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
Relmada Therapeutics Inc | 0.00 | -94.30m | 90.52m | 20.00 | -- | 1.26 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Eton Pharmaceuticals Inc | 34.30m | 913.00k | 91.20m | 30.00 | 104.94 | 5.89 | 49.22 | 2.66 | 0.0338 | 0.0338 | 1.33 | 0.6031 | 1.25 | 8.41 | 9.64 | 1,143,467.00 | 3.34 | -46.22 | 5.72 | -58.20 | 66.24 | 72.16 | 2.66 | -76.86 | 1.43 | -- | 0.2447 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
SCYNEXIS Inc | 140.39m | 101.33m | 91.24m | 29.00 | 1.20 | 1.23 | -- | 0.6499 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
Genelux Corp | 8.00k | -25.78m | 91.79m | 23.00 | -- | 4.77 | -- | 11,474.05 | -0.9811 | -0.9811 | 0.0003 | 0.5679 | 0.0004 | -- | -- | 347.83 | -131.24 | -- | -246.21 | -- | -- | -- | -322,287.50 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
Vor Biopharma Inc | 0.00 | -120.23m | 92.15m | 168.00 | -- | 0.7485 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 11.29m | 9.83% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 6.60m | 5.74% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 4.20m | 3.66% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.13m | 2.72% |
Millennium Management LLCas of 31 Mar 2024 | 2.94m | 2.56% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.88m | 2.51% |
Irenic Capital Management LPas of 31 Mar 2024 | 2.58m | 2.25% |
Redmile Group LLCas of 31 Mar 2024 | 1.91m | 1.66% |
Acadian Asset Management LLCas of 31 Mar 2024 | 1.59m | 1.38% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.27m | 1.11% |